Rentschler Biopharma signed a full CDMO licensing agreement with ATUM for the Leap-In Transposase® platform. ATUM will provide Rentschler with full access to its platform that combines proprietary re-coding algorithms, genetic vector elements, and a transposon-based mechanism for insertion of genetically stable elements into the genome.
According to Rentschler, the platform is particularly well suited for the production of standard antibodies as well as complex, multi-chain (e.g., 3+ chains) therapeutic proteins, such as bispecific monoclonal antibodies.
ATUM’s technology is expected to enhance Rentschler cell line development services and capabilities and complement the existing service offered via the CDMO’s strategic partner network, noted Frank Mathias, PhD, CEO of Rentschler Biopharma.
With this new collaboration, Rentschler Biopharma and ATUM will be able to offer an additional service that will produce stable, high titer manufacturing cell lines, thereby supporting a growing number of organizations in moving their biopharmaceuticals to the market faster and with lower manufacturing risk than using alternative strategies, he added.
Mathias also pointed out that the Leap-In Transposase platform will complement Rentschler’s recently implemented CHO GS KO platform for difficult-to-express proteins by providing solutions to translate medical research into biopharmaceuticals.
“At Rentschler Biopharma, we are always looking for innovative solutions across the entire value chain, from concept to market, by establishing strategic and valuable partnerships,” said Mathias.
“We are excited to combine our knowledge and in-house cell line development process with the deep expertise of ATUM, an industry leader in synthetic biology solutions for over a decade.”